title: Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.
abstract: While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better overall survival (OS, p=.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast (p=.031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome.
authors.affiliation: Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU Estaing, CREaT - EA 7283 INSERM et CIC501 Clermont-Ferrand, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: de Renzis
authors.affiliation: Laboratoire d'hématologie, CHU Purpan, Toulouse, France.
authors.forename: Veronique
authors.initials: V
authors.lastname: Mansat-De Mas
authors.affiliation: Hôpital Edouard Herriot, Lyon, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Wattel
authors.affiliation: Laboratoire d'hématologie, CHU Purpan, Toulouse, France.
authors.forename: Odile
authors.initials: O
authors.lastname: Beyne-Rauzy
authors.affiliation: Cliniques universitaires Saint-Luc and de Duve Institute, Université catholique de Louvain, Bruxelles, Belgium.
authors.forename: Laurent
authors.initials: L
authors.lastname: Knoops
authors.affiliation: Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU Estaing, CREaT - EA 7283 INSERM et CIC501 Clermont-Ferrand, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Cabrespine
authors.affiliation: Unite de cytogenetique Hematologique Service d'Hematologie Biologique, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris 6, Paris, France.
authors.forename: Zahia
authors.initials: Z
authors.lastname: Azgui
authors.affiliation: Service d'Hématologie Clinique, Hôpital Avicenne, APHP, et Paris 13 Université, Bobigny, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Ades
authors.affiliation: Clinical Investigation Center (CIC), Hôpital Saint-Louis, APHP and Paris 7 Université, Paris, France.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Kiladjian
authors.affiliation: Service d'Hématologie Clinique, Hôpital Avicenne, APHP, et Paris 13 Université, Bobigny, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
keywords: AML progression; JAK2V617F mutation; MDS; Prognosis; RARS-T